Clinical Trial Update: Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease [Phase 3]

View source ↗

Summary

This Phase 3 trial compares safinamide at 50 mg/day and 100 mg/day with placebo in mid-to-late stage Parkinson's disease, assessing efficacy and safety. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Xadago (safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED